The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Adaptimmune Therapeutics Plc ADR shares valued at $3,817,321 were sold by EcoR1 Capital, LLC on Jul 28 ’25. At $0.11 per share, EcoR1 Capital, LLC sold 33,931,740 shares. The insider’s holdings dropped to 130,492,680 shares worth approximately $13.05 million following the completion of this transaction.
Also, EcoR1 Capital, LLC sold 27,433,338 shares, netting a total of over 2,800,944 in proceeds. Following the sale of shares at $0.10 each, the insider now holds 100,371,882 shares.
Before that, EcoR1 Capital, LLC had sold 2,687,460 shares from its account. In a trade valued at $271,971, the 10% Owner traded Adaptimmune Therapeutics Plc ADR shares for $0.10 each. Upon closing the transaction, the insider’s holdings decreased to 2,687,460 shares, worth approximately $12.78 million.
As published in a research note from H.C. Wainwright on July 29, 2025, Adaptimmune Therapeutics Plc ADR [ADAP] has been rated down from a Buy to a Neutral. Analysts at Mizuho downgraded the stock from ‘”an Outperform”‘ to ‘”a Neutral”‘ outlook in a report released in late June. As of July 30, 2024, H.C. Wainwright has initiated its “Buy” rating for ADAP. Earlier on May 30, 2024, Scotiabank initiated its rating. Their recommendation was “a Sector outperform” for ADAP stock.
Analyzing ADAP Stock Performance
On last trading session,, Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] plunged -5.05% to $0.1. The stock’s lowest price that day was $0.0983, but it reached a high of $0.1134 in the same session. During the last five days, there has been a drop of approximately -65.66%. Over the course of the year, Adaptimmune Therapeutics Plc ADR shares have dropped approximately -92.83%.
Support And Resistance Levels for Adaptimmune Therapeutics Plc ADR (ADAP)
RSI (Relative Strength Index) is 27.36 on the 14-day chart, showing oversold technical sentiment.
Is Adaptimmune Therapeutics Plc ADR subject to short interest?
Stocks of Adaptimmune Therapeutics Plc ADR saw a sharp steep in short interest on 2025-07-15 dropping by -0.68 million shares to 3.88 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 4.56 million shares. A decline of -17.48% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.7 of the overall float, the days-to-cover ratio (short ratio) decline to 6.7.
Which companies own the most shares of Adaptimmune Therapeutics Plc ADR (ADAP)?
In terms of Adaptimmune Therapeutics Plc ADR share price expectations, FactSet research, analysts set an average price target of 3 in the next 12 months, up nearly 2900.0% from the previous closing price of $0.1. Analysts anticipate Adaptimmune Therapeutics Plc ADR stock to reach 4 by 2025, with the lowest price target being 1. In spite of this, 6 analysts ranked Adaptimmune Therapeutics Plc ADR stock as Buy at the end of 2025. On March 24, 2023, Bryan Garnier assigned a price target of “a Buy” to the stock and initiated coverage with a $3.60.
